A company developing a drug derived from the blood thinner heparin for a form of leukemia is planning to test it in patients with Covid-19 due to its anti-inflammatory and anti-clotting properties. Durham, North Carolina-based Chimerix said Wednesday that it would initiate a Phase II/III trial of dociparstat sodium, or DSTAT, in Covid-19 patients with acute lung […]

A Durham-based biopharmaceutical company says it has gotten the okay from the Food and Drug Administration to test its experimental cancer drug on COVID-19 patients in the U.S. The company, Chimerix, believes the drug, originally designed for acute myeloid leukemia, could address lung inflammation in COVID-19 patients as well as blood coagulation issues. The drug, DSTAT, is […]

Five biopharmaceutical industry CEOs discuss challenges their company’s have faced, along with best practices implemented in managing through the COVID-19 chaos […]